Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)
China
· Delayed Price · Currency is CNY 4.360
+0.010 (0.23%)
Mar 10, 2026, 10:25 AM CST
SHA:600572 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 6,489 | 6,426 | 6,652 | 5,945 | 6,531 | 5,863 | Upgrade
|
| Other Revenue | 89.02 | 89.02 | 80.59 | 54.95 | 37.67 | 46.16 | Upgrade
|
| Revenue | 6,578 | 6,515 | 6,733 | 6,000 | 6,568 | 5,909 | Upgrade
|
| Revenue Growth (YoY) | 1.80% | -3.23% | 12.21% | -8.64% | 11.15% | -12.70% | Upgrade
|
| Cost of Revenue | 3,127 | 3,101 | 2,835 | 2,470 | 2,626 | 2,088 | Upgrade
|
| Gross Profit | 3,450 | 3,414 | 3,897 | 3,531 | 3,942 | 3,821 | Upgrade
|
| Selling, General & Admin | 2,531 | 2,480 | 2,832 | 2,581 | 2,964 | 2,967 | Upgrade
|
| Research & Development | 275.53 | 300.02 | 298.09 | 195.72 | 202.49 | 184.99 | Upgrade
|
| Other Operating Expenses | 129.96 | 52.8 | -38.49 | 62.99 | 64.65 | 75.31 | Upgrade
|
| Operating Expenses | 2,936 | 2,834 | 3,093 | 2,840 | 3,268 | 3,239 | Upgrade
|
| Operating Income | 513.97 | 579.93 | 804.32 | 690.41 | 674.18 | 581.56 | Upgrade
|
| Interest Expense | -7.39 | -20.79 | -36.4 | -49.47 | -73.22 | -123.65 | Upgrade
|
| Interest & Investment Income | 82.53 | 101.92 | 135.27 | 89.35 | 2,611 | 302.83 | Upgrade
|
| Currency Exchange Gain (Loss) | 5.22 | 5.22 | 3.09 | -1.11 | 0.06 | -6.16 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.77 | -1.06 | -21.98 | -3.76 | -9.31 | -1.09 | Upgrade
|
| EBT Excluding Unusual Items | 590.56 | 665.22 | 884.3 | 725.42 | 3,203 | 753.5 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -52.99 | Upgrade
|
| Gain (Loss) on Sale of Investments | 121.39 | 30.27 | -146.04 | -238.23 | -714.69 | 34.63 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.49 | 20.55 | 35.68 | 36.02 | 42.22 | -4.86 | Upgrade
|
| Asset Writedown | -5.85 | -5.46 | -7.18 | -1.84 | -95.71 | -48.15 | Upgrade
|
| Other Unusual Items | 117.4 | 69.36 | 0.93 | 68.64 | 92.55 | 83.52 | Upgrade
|
| Pretax Income | 828.98 | 779.94 | 767.69 | 590.01 | 2,527 | 765.65 | Upgrade
|
| Income Tax Expense | 120.63 | 121.59 | 92.97 | 129.89 | 391.13 | 216.45 | Upgrade
|
| Earnings From Continuing Operations | 708.35 | 658.35 | 674.72 | 460.12 | 2,136 | 549.2 | Upgrade
|
| Minority Interest in Earnings | -20.36 | -35.94 | -83.15 | -102 | -118.31 | -95.9 | Upgrade
|
| Net Income | 687.99 | 622.42 | 591.57 | 358.12 | 2,017 | 453.3 | Upgrade
|
| Net Income to Common | 687.99 | 622.42 | 591.57 | 358.12 | 2,017 | 453.3 | Upgrade
|
| Net Income Growth | 41.33% | 5.21% | 65.19% | -82.25% | 345.06% | - | Upgrade
|
| Shares Outstanding (Basic) | 2,518 | 2,527 | 2,572 | 2,558 | 2,586 | 2,518 | Upgrade
|
| Shares Outstanding (Diluted) | 2,521 | 2,531 | 2,572 | 2,558 | 2,586 | 2,518 | Upgrade
|
| Shares Change (YoY) | -0.94% | -1.59% | 0.55% | -1.10% | 2.71% | -5.28% | Upgrade
|
| EPS (Basic) | 0.27 | 0.25 | 0.23 | 0.14 | 0.78 | 0.18 | Upgrade
|
| EPS (Diluted) | 0.27 | 0.25 | 0.23 | 0.14 | 0.78 | 0.18 | Upgrade
|
| EPS Growth | 42.85% | 7.09% | 64.29% | -82.05% | 333.33% | - | Upgrade
|
| Free Cash Flow | 861.44 | 721.9 | 689.5 | 863.73 | 309.8 | 789.3 | Upgrade
|
| Free Cash Flow Per Share | 0.34 | 0.28 | 0.27 | 0.34 | 0.12 | 0.31 | Upgrade
|
| Dividend Per Share | 0.150 | 0.150 | 0.200 | 0.150 | 0.160 | - | Upgrade
|
| Dividend Growth | -25.00% | -25.00% | 33.33% | -6.25% | - | - | Upgrade
|
| Gross Margin | 52.46% | 52.41% | 57.88% | 58.84% | 60.02% | 64.66% | Upgrade
|
| Operating Margin | 7.81% | 8.90% | 11.95% | 11.51% | 10.26% | 9.84% | Upgrade
|
| Profit Margin | 10.46% | 9.55% | 8.79% | 5.97% | 30.72% | 7.67% | Upgrade
|
| Free Cash Flow Margin | 13.10% | 11.08% | 10.24% | 14.39% | 4.72% | 13.36% | Upgrade
|
| EBITDA | 854.89 | 913.75 | 1,129 | 963.34 | 956.65 | 847.64 | Upgrade
|
| EBITDA Margin | 13.00% | 14.03% | 16.76% | 16.05% | 14.56% | 14.34% | Upgrade
|
| D&A For EBITDA | 340.92 | 333.82 | 324.35 | 272.93 | 282.47 | 266.07 | Upgrade
|
| EBIT | 513.97 | 579.93 | 804.32 | 690.41 | 674.18 | 581.56 | Upgrade
|
| EBIT Margin | 7.81% | 8.90% | 11.95% | 11.51% | 10.26% | 9.84% | Upgrade
|
| Effective Tax Rate | 14.55% | 15.59% | 12.11% | 22.02% | 15.48% | 28.27% | Upgrade
|
| Revenue as Reported | 6,578 | 6,515 | 6,733 | 6,000 | 6,568 | 5,909 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.